← All trials
NCT06870422
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2025
- Primary completion
- Apr 3, 2025
- Completion date
- Apr 14, 2025
- First posted
- Mar 11, 2025
- Last posted
- Apr 22, 2025
- Enrollment
- 28
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Teikoku Seiyaku Co., Ltd.Lead sponsor
- SocraTec R&D GmbHCollaborator
- Teikoku Seiyaku Co., Ltd.Official
- SocraMetrics GmbHCollaborator
- HWI pharma services GmbHCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.